Roivant Sciences Ltd.

NasdaqGS ROIV

Roivant Sciences Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2024: USD 419.36 M

Roivant Sciences Ltd. Net Cash Used Provided By Financing Activities is USD 419.36 M for the year ending March 31, 2024, a 0.00% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Roivant Sciences Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2024 was USD 419.36 M, a -16.04% change year over year.
Roivant Sciences Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2023 was USD 499.46 M, a 62.80% change year over year.
Roivant Sciences Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2022 was USD 306.79 M, a -32.76% change year over year.
Roivant Sciences Ltd. Net Cash Used Provided By Financing Activities for the year ending March 31, 2021 was USD 456.26 M, a 110.10% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: ROIV

Roivant Sciences Ltd.

CEO	Mr. Matthew Gline
IPO Date	Dec. 8, 2020
Location	United Kingdom
Headquarters	11-12 St. James's Square
Employees	908
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Vaccines

Description

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Key trends

Past 5 years